Arthritis and rheumatism 2010-01
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.
Related Questions
What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?
New comment by at NYU Langone Health ( September 25, 2020)
Arguments for intravenous as the preferred route of cyclophosphamide administration in rheumatic disease patients include the likely lower, if any, risk for urothelial cancer ...